hereditary leiomyomatosis and renal cell cancer

ClinicalMetric aggregates all active clinical trials for hereditary leiomyomatosis and renal cell cancer from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries. Trials are updated daily as new studies open, status changes, and enrollment targets are updated.

• Recruiting trials — currently enrolling participants, with eligibility criteria
• Phase 1–4 studies — from early safety trials to post-marketing surveillance
• NIH, pharmaceutical sponsor, and academic medical center studies worldwide
• AI-powered plain-language summary for every trial listing